Eisai Launches Leqembi for Early Alzheimer's Treatment in India After CDSCO Approval
Japanese pharmaceutical company Eisai has launched Leqembi (lecanemab) in India following approval from the Central Drugs Standard Control Organisation (CDSCO). Leqembi is the country's first disease-modifying therapy for early Alzheimer's disease, targeting mild cognitive impairment and mild dementia by clearing amyloid-beta plaques in the brain. The launch addresses India's rising dementia burden, with around 8.8 million people aged 60 and above affected in 2023, a number expected to nearly double by 2036. Patients require biomarker testing to confirm eligibility before treatment.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (58/100). Lens Score 43/100.
Outlets measured: businessstandard, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–62/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 3 Aug, 05:02 pm. Other outlets followed.
- 1